Leader in RNA interference translation
Alnylam is a leader in translating RNA interference (RNAi) into an innovative new class of drugs with the potential to transform the lives of people with rare genetic diseases, cardiometabolic diseases, infectious liver diseases, and central nervous system (CNS) and eye diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful and clinically validated approach for the treatment of a wide range of serious and debilitating diseases.
Founded in 2002 in the USA, Alnylam is based on a bold vision to turn scientific possibility into reality and its pioneering work has resulted in the first RNAi therapeutics approved in the
world. Alnylam is executing its “Alnylam P5x25” strategy to deliver transformative medicines for both rare and common diseases, benefiting patients globally through sustainable innovation and exceptional financial performance, resulting in a leading biotechnology company.
Alnylam still has five experimental drugs in the last stage of development and the goal is to start at least four clinical trials of new molecules per year by the end of 2025.
In 2016, it established a commercial headquarters in Europe and continues to invest responsibly in expanding its geographical presence in the region, currently employing more than 300 people in several countries, including Portugal.
Operate a revolution in biology for human health.
Build a leading, global, independent RNAi-based biopharmaceutical company.
Commitment to People, Innovation and Discovery, Sense of Urgency, Open Culture, and Passion for Excellence.